PE20181293A1 - Plataforma de armazon de nudo de cistina - Google Patents

Plataforma de armazon de nudo de cistina

Info

Publication number
PE20181293A1
PE20181293A1 PE2018000390A PE2018000390A PE20181293A1 PE 20181293 A1 PE20181293 A1 PE 20181293A1 PE 2018000390 A PE2018000390 A PE 2018000390A PE 2018000390 A PE2018000390 A PE 2018000390A PE 20181293 A1 PE20181293 A1 PE 20181293A1
Authority
PE
Peru
Prior art keywords
amino acid
seq
loop
natural amino
cystine knot
Prior art date
Application number
PE2018000390A
Other languages
English (en)
Inventor
Rami Hannoush
Harini Kaluarachchi
Aaron NILE
Cameron Noland
Yingnan Zhang
Lijuan Zhou
Xinxin Gao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20181293A1 publication Critical patent/PE20181293A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a un peptido de nudo de cistina (CKP) de origen no natural que se une al factor de crecimiento endotelial vascular A (VEGF-A), donde el CKP comprende la estructura de armazon de cistina: Z1C1L1C2L2C3L3C4L4C5L5C6Z2, donde Z1 y Z2 son cualquier aminoacido; L1 es el bucle 1 y tiene una estructura seleccionada del grupo que consiste en: X1X2X3X4X5X6 (SEQ ID NO:2), X1X2X3X4X5X6X7 (SEQ ID NO:3), X1X2X3X4X5X6X7X8 (SEQ ID NO:4), X1X2X3X4X5X6X7X8X9 (SEQ ID NO:5) y X1X2X3X4X5X6X7X8X9X10 (SEQ ID NO:6), donde cada uno de X1 a X10 es cualquier aminoacido; L2 es el bucle 2 y tiene la estructura: X1X2X3X4X5 (SEQ ID NO:7), donde cada X1 a X5 es cualquier aminoacido o un aminoacido no natural; L3 es el bucle 3 y tiene la estructura X1X2X3, donde cada X1 a X3 es cualquier aminoacido o un aminoacido no natural; L4 es el bucle 4 y tiene la estructura X1, donde X1 es cualquier aminoacido o un aminoacido no natural; L5 es el bucle 5 y tiene la estructura X1X2X3X4X5 (SEQ ID NO:7), donde cada uno de X1 a X5 es cualquier aminoacido o un aminoacido no natural; donde el aminoacido no natural es L-propargilglicina-PEG6-, L-sulfotirosina, entre otros. Tambien se refiere a composiciones que comprende dicho peptido. La presente invencion es util para el tratamiento de un trastorno ocular tal como enfermedad ocular proliferativa o trastorno ocular caracterizada por angiogenesis excesiva
PE2018000390A 2015-09-15 2016-09-15 Plataforma de armazon de nudo de cistina PE20181293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562219063P 2015-09-15 2015-09-15

Publications (1)

Publication Number Publication Date
PE20181293A1 true PE20181293A1 (es) 2018-08-07

Family

ID=57068206

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000390A PE20181293A1 (es) 2015-09-15 2016-09-15 Plataforma de armazon de nudo de cistina

Country Status (23)

Country Link
US (7) US10428125B2 (es)
EP (1) EP3350215A1 (es)
JP (2) JP7166916B2 (es)
KR (1) KR20180052718A (es)
CN (3) CN114591422A (es)
AR (1) AR106032A1 (es)
AU (2) AU2016323445B2 (es)
BR (1) BR112018002263A2 (es)
CA (1) CA2996006A1 (es)
CL (2) CL2018000668A1 (es)
CO (1) CO2018002510A2 (es)
CR (1) CR20180169A (es)
HK (1) HK1253318A1 (es)
IL (2) IL294568A (es)
MA (1) MA42828A (es)
MX (1) MX2018002922A (es)
MY (1) MY190552A (es)
PE (1) PE20181293A1 (es)
PH (1) PH12018500577A1 (es)
RU (1) RU2770384C2 (es)
TW (1) TWI799366B (es)
UA (1) UA125505C2 (es)
WO (1) WO2017049009A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
AU2021289738A1 (en) 2020-06-11 2022-12-15 Genentech, Inc. Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918814A (en) 1907-10-30 1909-04-20 Handy Mfg Company Funnel.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
EP1060194A1 (en) 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
JP2003534813A (ja) 2000-06-01 2003-11-25 アムジェン インコーポレーテッド シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2002100318A2 (en) 2001-06-12 2002-12-19 Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
WO2003029275A2 (en) 2001-10-03 2003-04-10 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
SI1844337T1 (sl) 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
CA2614358A1 (en) 2005-06-29 2007-01-04 Roselli, Patrizia Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy
US20070212703A1 (en) * 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
TW200732347A (en) 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
WO2007131050A2 (en) 2006-05-02 2007-11-15 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2091482A2 (en) 2006-12-01 2009-08-26 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
JP6073043B2 (ja) 2007-08-21 2017-02-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
EP2274008B1 (en) 2008-03-27 2014-02-26 ZymoGenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010048588A2 (en) * 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
CN102365109B (zh) 2009-01-29 2015-06-03 弗赛特影像4股份有限公司 后段给药
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en) 2009-12-21 2011-08-25 Adrian Raiche Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
EP2515864A4 (en) 2009-12-23 2013-09-11 Psivida Inc DELAYED RELEASE DELIVERY DEVICES
US8339139B2 (en) * 2010-01-29 2012-12-25 Infineon Technologies Ag System and method for testing a circuit
JP6170435B2 (ja) 2010-11-08 2017-07-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ノッチンペプチドを含む融合タンパク質及びその使用
BR112013020874A2 (pt) * 2011-02-18 2019-05-21 Endo Pharmaceuticals Inc. composto, regime, método para a preparação do referido composto, e, uso de um composto
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
EP2890389A1 (en) 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺

Also Published As

Publication number Publication date
AU2016323445B2 (en) 2021-04-01
WO2017049009A8 (en) 2018-02-22
AU2021204400B2 (en) 2023-02-02
EP3350215A1 (en) 2018-07-25
TW201717993A (zh) 2017-06-01
CA2996006A1 (en) 2017-03-23
US20180291069A1 (en) 2018-10-11
US10428125B2 (en) 2019-10-01
US20200140498A1 (en) 2020-05-07
MY190552A (en) 2022-04-27
CN114591422A (zh) 2022-06-07
WO2017049009A1 (en) 2017-03-23
CN114805528A (zh) 2022-07-29
IL294568A (en) 2022-09-01
CL2018000668A1 (es) 2018-07-20
KR20180052718A (ko) 2018-05-18
JP7166916B2 (ja) 2022-11-08
US20200115424A1 (en) 2020-04-16
IL257399A (en) 2018-04-30
CR20180169A (es) 2018-04-24
PH12018500577A1 (en) 2018-10-15
UA125505C2 (uk) 2022-04-13
RU2018113442A (ru) 2019-10-16
MX2018002922A (es) 2018-06-07
IL257399B (en) 2022-08-01
US20200325187A1 (en) 2020-10-15
CL2020001781A1 (es) 2020-10-23
JP2018533912A (ja) 2018-11-22
US11407794B2 (en) 2022-08-09
AU2016323445A1 (en) 2018-03-01
HK1253318A1 (zh) 2019-06-14
BR112018002263A2 (pt) 2018-09-18
JP2022130481A (ja) 2022-09-06
US11155586B2 (en) 2021-10-26
RU2018113442A3 (es) 2020-02-17
CN108026162B (zh) 2022-04-05
CO2018002510A2 (es) 2018-05-31
RU2770384C2 (ru) 2022-04-15
US20170129927A1 (en) 2017-05-11
CN108026162A (zh) 2018-05-11
US20230174596A1 (en) 2023-06-08
TWI799366B (zh) 2023-04-21
MA42828A (fr) 2018-07-25
AR106032A1 (es) 2017-12-06
US20200231636A1 (en) 2020-07-23
US11078243B2 (en) 2021-08-03
AU2021204400A1 (en) 2021-07-22
US10696721B2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
CL2020002796A1 (es) Derivados de gip y usos de estos
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
PE20181517A1 (es) Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer
MX2016016868A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
GT201300295A (es) "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales"
AR081361A1 (es) Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
EA201990071A1 (ru) Композиция пептидной вакцины
PE20181293A1 (es) Plataforma de armazon de nudo de cistina
MX2018002524A (es) Composicion farmaceutica que contiene, como ingrediente activo, proteina de fusion en la que el peptido de tumor-penetrante y el agente anti-angiogenesis se funden, para prevenir y tratar el cancer o enfermedades relacionadas a la angiogenesis.
PE20190626A1 (es) Composiciones y metodos para modular la expresion del factor b del complemento
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
MX2018015410A (es) Esteres de oxaborol y sus usos.
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CL2020002561A1 (es) Composiciones y métodos para el tratamiento de la distrofia macular
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
CU20170038A7 (es) Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
MX2018002924A (es) Anticuerpos monoclonales altamente potentes para factores angiogenicos.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии